ICI is a monoclonal antibody antagonist that increases the body’s immune response to cancer cells by blocking intrinsic immune response downregulators, such as CTLA-4 and programmed cell death 1 (PD-1) or its ligand programmed cell death ligand 1 (PD-L1). Here, PDCD1 is linked to cancer.